The Lantern is billed as an AI platform aimed at accelerating revenue workflows, claiming 19% increase in average deal size through timed upsell outreach. The Champion Agent tracks job changes across the customer base and improve response rates for certain teams. In pharma, Lantern Pharma reports 2026 progress, reducing R&D spend by 47% while progressing clinical programs, launching an AI platform with Zeta.ai and expanding an AI Center of Excellence in India to scale RADR. These developments illustrate Lantern's growth into AI-driven sales intelligence, supported by ongoing financing to fuel expansion.
Sources
lantern News and Updates from The Economictimes.com
economictimes.indiatimes.comLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform...
www.innovationopenlab.comDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million Q1 net loss reduced 27% year-over-year while progressing multiple...
www.pharmiweb.comBrowse, deploy, and customize AI agents that automate every critical revenue function—from champion tracking to intent monitoring, all available in minutes.
withlantern.comnews
www.newswire.caDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million
natlawreview.com